Similarly, in the lungs, expression levels of these five proteins had a 1.6-fold to 5.4-fold increase in the vehicle in comparison with the sham group.
In lung cancer, expression levels of both HGF and c-Met have been associated with advanced tumor stage and worse clinical outcome [ 3].
The rationale of using miRNA as therapeutics agents in lung cancer management is based on the assumption that miRNAs have an important role in lung development, their expression levels are deregulated in lung cancer patients compared with healthy subjects and that modulation of miRNA expression, both in vitro and in vivo, can modify the cancer phenotype.
As with the miR-17-92 miR-17-92 miR-17-922-367 cluster (Mirc20) is also expressed athearly stages of lung development, and expression levels decline rapidly as development proceeds.
Lung tissue mRNA expression levels of Inhba were not altered by treatment with sActRIIB-Fc (not shown).
This is of particular interest, as an up-regulation of TLR4 expression has been reported recently in human adenocarcinoma of the lung with TLR4 expression levels correlating with malignancy [ 26].
In some cancers (gastric, hepatocellular, prostate, ovarian, breast, colon, and non-small cell lung cancers), high expression levels of MIF and/or CD74 correlate with poor prognoses (Meyer-Siegler et al, 2002; Tomiyasu et al, 2002; Hagemann et al, 2005; Hira et al, 2005; Xu et al, 2008; Xia et al, 2009).
The miRNAs from five of these clusters (mir-16-1-mir-15a, mir-16-2-mir-15b, let-7f-let-7a-1, let-7j-let-7k and mir-23b-mir-27b-mir-24) identified in both lungs and tracheae were significantly down-regulated in infected lungs compared to non-infected lungs and also had higher expression levels in non-infected lungs than non-infected tracheae.
Besides tumour cells, mouse lung tissues also expressed higher mRNA expression levels for the mouse receptor.
